Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term results of thumb carpometacarpal joint arthrodesis.

Archives of orthopaedic and trauma surgery·2026
Same author

Factors associated with variation in treatment of the distal radioulnar joint after plate fixation of distal radial fractures.

The Journal of hand surgery, European volume·2026
Same author

Gut colonization with multidrug-resistant organisms in hospitalized patients with gastrointestinal illness: A single-centre, cross-sectional study.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2026
Same author

Restoration of CPAK type in total knee arthroplasty does not lead to superior clinical outcome: A study based on arthroplasty registry data.

Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA·2026
Same author

Combined trochleoplasty and medial patellofemoral ligament reconstruction reduces patellar height.

Journal of experimental orthopaedics·2026
Same author

No significant side-to-side differences in retropatellar load distribution using more than 7.5 years after isolated MPFL reconstruction: A CT-osteoabsorptiometry pilot study in nine patients.

Journal of experimental orthopaedics·2026

Related Experiment Video

Updated: Jun 21, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Clopidogrel pharmacogenetics and its clinical implications.

Mukesh Singh1, Bipin Thapa, Rohit Arora

  • 1Section of Cardiology, Department of Internal Medicine, Rosalind Franklin University of Medicine & Science, Chicago Medical School, North Chicago, IL, USA. drmukeshsingh@yahoo.com

American Journal of Therapeutics
|July 29, 2009
PubMed
Summary

Genetic variations influence how individuals respond to clopidogrel, an antiplatelet medication. Understanding these pharmacogenetic factors is key to managing drug response variability and improving patient outcomes.

Related Experiment Videos

Last Updated: Jun 21, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Area of Science:

  • Pharmacogenetics
  • Cardiovascular Pharmacology
  • Thrombosis Research

Background:

  • Individual variability in platelet reactivity impacts hemostasis and thrombosis.
  • Response to clopidogrel, an antiplatelet drug, shows significant interindividual differences, with nonresponse rates from 4%-30%.
  • Genetic variations in hemostatic and thrombotic systems are linked to antithrombotic drug response.

Purpose of the Study:

  • To review the pharmacogenetics of clopidogrel.
  • To explore the relationship between genetic factors and clopidogrel response variability.
  • To discuss the clinical implications of clopidogrel pharmacogenetics.

Main Methods:

  • Literature review of pharmacogenetic studies on clopidogrel.
  • Analysis of genetic polymorphisms affecting clopidogrel metabolism and action.
  • Examination of variations in hepatic enzymes (CYP 1A2, CYP3A4, CYP2C19), P2Y12 receptor, and integrin pathways.

Main Results:

  • Polymorphisms in CYP enzymes, P2Y12 receptor, and integrin alphaIIbbeta3/alpha2beta1 can affect platelet response to clopidogrel.
  • These genetic variations contribute to the observed variability in clopidogrel efficacy.
  • Understanding these polymorphisms is crucial for predicting and managing patient response.

Conclusions:

  • Pharmacogenetics plays a significant role in clopidogrel response variability.
  • Genetic testing may help personalize clopidogrel therapy.
  • Further research is needed to fully elucidate the clinical utility of clopidogrel pharmacogenetics.